4//SEC Filing
Wassil Jim 4
Accession 0001649094-25-000010
CIK 0001649094other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 7:20 PM ET
Size
12.4 KB
Accession
0001649094-25-000010
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Wassil Jim
CHIEF OPERATING OFFICER
Transactions
- Sale
Common Stock
2025-02-03$86.00/sh−5,314$456,983→ 208,381 total - Sale
Common Stock
2025-02-03$87.94/sh−20$1,759→ 205,695 total - Exercise/Conversion
Common Stock
2025-02-03$2.42/sh+8,000$19,360→ 213,695 total - Sale
Common Stock
2025-02-03$86.67/sh−2,666$231,049→ 205,715 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-03−8,000→ 2,638 totalExercise: $2.42Exp: 2029-12-16→ Common Stock (8,000 underlying)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $85.32 to $86.295. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $86.365 to $87.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Option is fully vested and exercisable.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001813798
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 7:20 PM ET
- Size
- 12.4 KB